New drug combo tested to keep advanced lung cancer at bay
NCT ID NCT04743505
Summary
This study is testing if adding an investigational drug called APL-101 to the standard first-line treatment (osimertinib) can help control advanced lung cancer for a longer period. It is for adults whose cancer has a specific genetic change (EGFR mutation) and has not worsened after 8-12 weeks on osimertinib alone. The main goals are to find a safe dose of APL-101 and see if the combination delays cancer progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.